The conserved serine/threonine kinase mTOR (the mammalian target of rapamycin), a
downstream effector of the PI3K/AKT pathway, forms two distinct multiprotein complexes …

Tumours comprise multiple phenotypically distinct subpopulations of cells, some of which
are proposed to possess stem cell‐like properties, being able to self‐renew, seed and …

The target of rapamycin (TOR) is a highly conserved protein kinase and a central controller
of growth. Mammalian TOR complex 2 (mTORC2) regulates AGC kinase family members …

This study addresses the role of PTEN loss in intrinsic resistance to the BRAF inhibitor
PLX4720. Immunohistochemical staining of a tissue array covering all stages of melanocytic …

In desmoplastic melanoma, tumor cells and tumor-associated fibroblasts are the major
dominators playing a critical role in the fibrosis morphology as well as the …

The recent years have seen a significant shift in the expectations for the therapeutic
management of disseminated melanoma. The clinical success of BRAF targeted therapy …

The Mitogen Activated Protein Kinase (MAPK) pathway plays a key role in melanoma
development making it an important therapeutic target. In normal cells, the tightly regulated …

Melanoma progression is typically depicted as a linear and stepwise process in which
metastasis occurs relatively late in disease progression. Significant evidence suggests that …

MicroRNAs (miRNAs) are a type of endogenous noncoding small RNAs involved in the
regulation of multiple biological processes. Recently, miR-29 was found to participate in …

The discovery of activating BRAF V600E mutations in 50% of all cutaneous melanomas has
revolutionized the understanding of melanoma biology and provided new strategies for the …